Member Info for Ivyspivey

Morning yes CW thanks for posting that excellent article that covers all aspects of the merger in an extremely balanced and informative way.

The other consideration is whether there is a clause in the Merck agreement and how they react to it. I can’t see any objection from them but they may use it as a negotiating tool

Chester the easiest way to sort this imo is to out CVRs on any shares issued linked to milestones like getting the Merck payment in so these issues can be sorted if all parties are willing

Must be the heat Ratty but am agreeing with you :)

As for your question and you don’t need to believe me I love the ups and downs on AIM and that is why I can never just stick with one share.

Sadly in some ways the main way you can measure getting your calls more right than wrong is how you much money you make or lose but for me like most things in life it is not about the end game but the journey.

Anyway footy soon and you will accuse me of being contrary again but in the case of England in the World Cup I would accept an awful journey for a great endgame but like Wildforces sentiment they are closely correlated.

Will end it now as footy soon but equally for the record.

We may have disagreed on some things but C7 was a fantastic advocate for SCLP and fully appreciate how heartfelt his loss was to this community and in particular to those who were his friend like yourself.

I don’t claim to hold plenty here just enough to be content and I have never claimed it will make me rich as it won’t make any difference to me either way but if you think becoming rich is something I strive for you don t know me at all

Agree WF we imo should all wish success to all efforts to fight this dreadful disease as it really is a huge past,present and future threat to many precious family and friends of all of us on here.

However, I would think the vast bulk are invested here to generate a monetary return and of course many will give money direct to likes of CRUK.

Fortunately I dint think the two things are mutually exclusive and the Merck mantra was Followed the Science and the more the successfulmthecSciencevthen the profits will follow and I strongly suspect the same here

Of course it’s a bit of fun and I would be delighted if this goes up 10 or 20x as I would do well enough. Obviously not as well as those who hold millions of shares but then again I am not greedy and of course I don’t go through the discomfort of seeing my holding drop by £250k in a few weeks like your mate.

But that is the risk we take here so be humble if things go well and respectful when things go the other way. That is one of the reasons I don’t like your mate as he is insanely jealous of anyone else’s achievements and glorify s anyone else’s misery. But guess that is the difference between us.

But yep HAGW

Ratty you really should know better. Yes I do question news or speculation in Company’s I am invested in so that I can try and make wise or “ astute” decisions and not just “ trust” the views of others including CEOs where as you say you can lose money. However this particular CEO actually did list an AIM biopharma onto Nasdaq and before that he was a Global Director of Merck, where I met him , of their Vaccine and Oncology platforms so exactly the kind of guy that would ultimately decide whether they would decide to buy I to SCLP.

Yes he failed but guess he may have a better insight into the prospects of SCLP than a self educated builder and an ex traffic cop.

So please tell me why you spend half your time in the last 10 years on another BB where you don’t hold shares and are completely negative there and try and save them from a share you don’t even own.

I have always said the Science here is compelling and the PFS figure is outstanding so no argument from me there.I just wish the “ glee club” of which you are a fully paid up member would accept some of the facts that the “ astute” occasionally raise. Like there is some risk in investing here? The SP here may not reach £8 a share within anyone’s lifetime? The ones who have traded this share over the last 10 years have done much better than those who have just bought and hold?. There are other shares to invest in which are equally as good if not better than SCLP in terms of risk/ reward?

I get some right and some wrong and that is the nature of investing on AIM and I have never claimed to be any better or worse than anyone else here. Unlike your good mate who has never professed to be wrong on any matter and you laud as some investing genius when we know has been proven to not be very good at all at playing this game.

ATB

As you say the comment about “ SCLP inheriting the cash” was lifted off this BB but was to illustrate the misconception that some have as you clarified.

Our specific point of disagreement is whether Neuphoria is a clean cash shell.You claim it is whereas I am more sceptical about it being classed as that given its current assets of which I can assure you I did some research.

As you say it is all about the detail of the deal and it is only then that we can truly judge whether it is a good deal. Being “slightly negative” or I would call it questioning and not jumping ahead of myself is again imo a more realistic attitude than the ultra positive nothing can go wrong no risk approach populated by some on here.

MP Neuphoria Neuphoria Therapeutics maintains an exclusive, long-standing research collaboration and licensing agreement with Merck & Co. to develop central nervous system (CNS) therapies. The partnership focuses on advancing positive allosteric modulator candidates, most notably MK-1167, which is being evaluated by Merck in Phase 2 clinical trials for Alzheimer's disease.Under this alliance, Neuphoria is eligible for up to $450 million in developmental and commercial milestone payments, in addition to royalties on future net sales, with Merck funding all development and commercialization costs. Merck's advancement of MK-1167 into mid-stage studies previously triggered a $15 million milestone payment to Neuphoria.

So hardly a clean shell. If they believe in the value of this asset then what value will SCLP have to pay to acquire it ,

I am not doubting Phil is a clever guy and have spoken to people who have worked with him and testify to that but it looks more like he wants to build a bigger pharma which incorporates both lots of assets and some of the figures put on here have suggested an 80/20 split in favour of SCLP but we do not have that detail.but why would SCLP give away any %age of their own Science to buy someone else’s ( not aligned) when according to some the SCLP Science is worth so much more.

Someone else said that SCLP would inherit the cash pile as if that would not be included in the price that SCLP would pay.

My point about the many is that a lot of folk talked about a US listing but no one mentioned an RTO of a non clean SPAC ( we disagree on whether we view it as clean or not) but it is all about how much SCLP pay for the assets which we dint know yet.

Getting back to the knockout deal of course a deal of some kind may be announced but the fact is that if the likes of Merck really wanted iSCIB then they would buy it and I can assure you the price would not be a deal breaking issue imo.

MP don’t think we are surprised by a Nasdaq listing but.

1. Think many thought and wanted a knock out deal being on the table. This looks very unlikely.

2. Many thoughts US listing would be done by IPO or possibly RTO into a clean SPAC not into an existing biopharma with its own pipeline not aligned toSCLP.

3. It may be value enhancing or may or not but again many thought the SCLP assets were so good why would you want to supplement it with anything else.

4. I doubt this isa Plan B as the upfront costs involved of advancing the deal and preparing the ground will be substantial at a tie when we know SCLP need money soon so suggest it is either complentary plan or Plan A as why would you spend a lotof money asakind of insurance

Morning Chester,

I agree with you I think it is very relevant as Neuphoria is not a pure clean SPAC that SCLP are paying for.

Yes it gives them a possible US listing which is potentially much more value reflective of the excellent Science here but we need much more detail to be able to be certain of whether it is a wise move or not.

As you say Chester SCLP will acquire all of those things you highlight and whilst debt etc can easily be calculated putting a value against the other pipeline assets can be much more difficult. What happens in terms of progressing their pipeline which is generally not well aligned with SCLPs, what resources may or may not be allocated.

How do you manage and integrate the legacy folk on both sides?. Do you pay off the Neuphoria staff by giving them favourable legacy share options and is it going to be based innUS as there is a difference between being US based and US listed.

Will it keep its AIM listing or go solely US.

Anyone with experience of POLB will recognise the dangers of doing this type of reverse Nasdaq

Iisting.

As I say we need much more detail but I for one would have been far happier with the knockout deal even at a much lower price than some on here have predicted as we would have had that choice to stay or twist and also would have given a fantastic external validation of the Science as well as the financial clout to move forward.

We know the Science is compelling and the SP is reflective of the situation here but we just need to get a better perspective of potential outcomes here and in my experience if something sounds so good then it is either not true or probably in the case of SCLP it os true but if the big boys want in they will find a mechanism for getting what they want at a price they want to pay and not what SH may want them to pay.

Vascular more old info but illustrative of the huge progress that has been made by SCLP.

Back in 2015 RG said at the AGM how proud he was to be welcoming shareholders to a £30m market cap outfit. Although the SP was very similar look at the market cap now to see the outstanding success that has allowed SCLP to become such a major player with unlimited potential.

CW it could be licensed out but it is an entirely different market so SCLP would need to prove it and after they abandoned the Covidity Vax it would imo moot be worth it .

As I said the oncology space is much harder to achieve success in and the SCLP assets are absolutely first class and are the absolute priority for SCLP.

Some may disagree but myself and a few other posters have always felt the science here is compelling and increasingly it has become obvious that the potential here is indeed extremely high. Yes we may have traded a few more on the spikes than maybe some of LTH but please do not see that as a sign of lack of confidence here just reacting to how we think the market behaves and of course we see other attractive stocks in the market.

Again we may disagree with some of the touted valuations and the concept of risk and none of us can predict those with certainty but please just accept us as having a different viewpoint on the journey of travel and final destination as some on here rather than some binary disagreement about the fantastic situation SCLP find themselves in .

Enjoy B/ H all

CW the Oxford Ebola Vax is based on their ChAdOx technology which uses the Chimpazee Adenovirus as the Vector to get the Glyco protein into the body. Very similar to their Covid Vax which had no connection to the SCLP approach which uses different technology.

We know getting Vax to work vs Cancer targets is more difficult that infectious disease and that is why I consider SCLP is focused in that area rather than have any connection you highlight

Value inflection

Morning Chester,

Really good to see the recent increase in SP and plenty more to go.

I do think it is likely imo they will go it alone and I understand that is what RM would prefer but of course it depends on the value of any deal.and will be pharma interest and see GSK are looking to oncology as a big strategic focus.

Like you I would prefer a payout now but appreciate others may favour waiting another few years for val

Enjoy Thailand and a nice response.

I do think the chances of success in the phase 3 are very high given p2 results and general levels of confidence but as Phil said there is still risk albeit relatively low and of course there are many other shots at goal.

I guess like many I would prefer a deal and can decide to move on and focus on the other assets but obviously if SCLP go it alone then the potential value is much higher and the timeline of course is much longer.

Very similar a mining share I am in after a 10 year plus journey do you take the deal for a very nice return or do you hold out for the mega pay off which may or may not come.

Personally I prefer the bird in hand and leave some for the ride but we all want different things

No worries EE and the flash update was probably already posted and fully understand you wanting to see more detail.

As an aside and I do think Frank G s question was very interesting why don’t you give him a call and I certainly have spoken to him and found him very responsive. obviously within the strict limits of being a retail investor but he is a big fan of SCLP and I find his views relevant.

My understanding as well is that most of the US funds like RM prefer the assets to be developed until the full value inflection point but of course a blockbuster offer could change all that

EE TD have updated

https://www.trinitydelta.org/research-notes/h126-solid-iscib1-data-underpins-planned-progress/

They also updated after the FDA news but above is after interims